» Articles » PMID: 30392575

Dose-response Relationship Between Docosahexaenoic Acid (DHA) Intake and Lower Rates of Early Preterm Birth, Low Birth Weight and Very Low Birth Weight

Overview
Specialty Endocrinology
Date 2018 Nov 6
PMID 30392575
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

As previously reported, intention-to-treat findings from our phase III randomized clinical trial found that a supplement of 600 mg docosahexaenoic acid (DHA)/day during the last half of pregnancy reduced the incidence of early preterm birth (ePTB, <34 weeks gestation) and very low birth weight (VLBW < 1500 g) offspring. Given the potentially immense clinical significance of these findings, the goal of this secondary analysis was to (1) identify maternal characteristics related with capsule intake (i.e. DHA dose exposure) and (2) determine if DHA dose was associated with low (<2500 g) and very low birth weight after controlling for any relevant maternal characteristics. Three hundred forty-five pregnant mothers were recruited from hospitals in the Kansas City metropolitan area between 2006 and 2011. Most participants (n = 299) were from the phase III trial mentioned above, but we also included 46 participants from a second smaller, randomized trial that utilized an identical intervention design and was conducted concurrent to the larger trial. Both trials assigned participants to either 3 daily capsules of vegetable oil without DHA (n = 169) or 3 daily capsules of 200 mg DHA each (n = 176). Total capsules consumed was recorded by pharmacy supervised capsule count or participant self-report when needed. Maternal age, education, race and gestational age at delivery as well as infant birth weight were available for both trials. A Bayesian linear model indicated capsule intake increased with maternal age (p = 0.0100) and years of education (p = 0.0002). A Bayesian bivariate mixture-model associated capsule intake with simultaneous lower probability of ePTB, low birth weight (LBW, <2500 g) and VLBW (p = 0.0327). This, in conjunction with the positive findings in the clinical trial, support the need for future research to examine intervention methods to improve capsule compliance strategies in younger and less educated mothers.

Citing Articles

Maternal dietary DHA and EPA supplementation ameliorates adverse cardiac outcomes in THC-exposed rat offspring.

Lee K, Sarikahya M, Cousineau S, Yeung K, Lucas A, Loudon K Sci Rep. 2025; 15(1):8316.

PMID: 40064971 PMC: 11894106. DOI: 10.1038/s41598-025-92844-6.


Impact of Maternal Essential Fatty Acid Intake on the Birth Weight of Infants.

Masina M, Medithi S, Muley A J Mother Child. 2023; 27(1):147-157.

PMID: 37843970 PMC: 10578463. DOI: 10.34763/jmotherandchild.20232701.d-22-00052.


Predictors of compliance with higher dose omega-3 fatty acid supplementation during pregnancy and implications for the risk of prematurity: exploratory analysis of the ORIP randomised trial.

Sullivan T, Yelland L, Gibson R, Thakkar S, Huang F, Best K BMJ Open. 2023; 13(9):e076507.

PMID: 37739459 PMC: 10533701. DOI: 10.1136/bmjopen-2023-076507.


Early and late preterm birth rates in participants adherent to randomly assigned high dose docosahexaenoic acid (DHA) supplementation in pregnancy.

Carlson S, Gajewski B, Valentine C, Sands S, Brown A, Kerling E Clin Nutr. 2023; 42(2):235-243.

PMID: 36680919 PMC: 10546372. DOI: 10.1016/j.clnu.2023.01.009.


The value of a two-armed Bayesian response adaptive randomization trial.

Gajewski B, Carlson S, Brown A, Mudaranthakam D, Kerling E, Valentine C J Biopharm Stat. 2022; 33(1):43-52.

PMID: 36411742 PMC: 9812849. DOI: 10.1080/10543406.2022.2148161.


References
1.
Ramakrishnan U, Stein A, Parra-Cabrera S, Wang M, Imhoff-Kunsch B, Juarez-Marquez S . Effects of docosahexaenoic acid supplementation during pregnancy on gestational age and size at birth: randomized, double-blind, placebo-controlled trial in Mexico. Food Nutr Bull. 2010; 31(2 Suppl):S108-16. DOI: 10.1177/15648265100312S203. View

2.
Gajewski B, Reese C, Colombo J, Carlson S . Commensurate Priors on a Finite Mixture Model for Incorporating Repository Data in Clinical Trials. Stat Biopharm Res. 2016; 8(2):151-160. PMC: 4915595. DOI: 10.1080/19466315.2015.1133453. View

3.
Glass H, Costarino A, Stayer S, Brett C, Cladis F, Davis P . Outcomes for extremely premature infants. Anesth Analg. 2015; 120(6):1337-51. PMC: 4438860. DOI: 10.1213/ANE.0000000000000705. View

4.
Makrides M, Gibson R, McPhee A, Yelland L, Quinlivan J, Ryan P . Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA. 2010; 304(15):1675-83. DOI: 10.1001/jama.2010.1507. View

5.
Yelland L, Gajewski B, Colombo J, Gibson R, Makrides M, Carlson S . Predicting the effect of maternal docosahexaenoic acid (DHA) supplementation to reduce early preterm birth in Australia and the United States using results of within country randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2016; 112:44-9. PMC: 5028118. DOI: 10.1016/j.plefa.2016.08.007. View